Stocktoria
RELMADA THERAPEUTICS, INC. RLMD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-03-03
RELMADA THERAPEUTICS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $26.9M | $46.2M | $54.8M | $113.3M | $90.6M |
| Operating income | -$59.1M | -$83.9M | -$103.7M | -$161.2M | -$125.7M |
| Net income | -$57.4M | -$80.0M | -$98.8M | -$157.0M | -$125.8M |
| EPS (diluted) | $-1.45 | $-2.65 | $-3.28 | $-5.30 | $-7.16 |
| Operating cash flow | -$45.8M | -$51.8M | -$51.7M | -$103.8M | -$91.9M |
| Cash & equivalents | $3.5M | $3.9M | $4.1M | $5.4M | $44.4M |
| Total assets | $94.0M | $45.8M | $97.6M | $152.9M | $223.3M |
| Total liabilities | $7.5M | $10.3M | $12.2M | $12.5M | $15.1M |
| Shareholders' equity | $86.5M | $35.5M | $85.4M | $140.4M | $208.3M |
Source: SEC EDGAR filings · CIK 0001553643 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.